Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-VITRO AND IN-VIVO STUDIES ON THE DEVELOPMENT OF THE ALPHA-EMITTINGRADIONUCLIDE BISMUTH-212 FOR INTRAPERITONEAL USE AGAINST MICROSCOPIC OVARIAN-CARCINOMA
Autore:
ROTMENSCH J; WHITLOCK JL; SCHWARTZ JL; HINES JJ; REBA RC; HARPER PV;
Indirizzi:
UNIV CHICAGO,DEPT OBSTET & GYNECOL,GYNECOL ONCOL SECT,MC2050,5841 S MARYLAND AVE CHICAGO IL 60637 UNIV CHICAGO,DEPT NUCL MED CHICAGO IL 60637 UNIV CHICAGO,DEPT SURG CHICAGO IL 60637 UNIV WASHINGTON,DEPT RADIAT ONCOL SEATTLE WA 98195 ARGONNE NATL LAB,DEPT CHEM ARGONNE IL 60439
Titolo Testata:
American journal of obstetrics and gynecology
fascicolo: 4, volume: 176, anno: 1997,
pagine: 833 - 840
SICI:
0002-9378(1997)176:4<833:IAISOT>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PB-212;
Keywords:
ALPHA-EMITTING ISOTOPES; BISMUTH 212; OVARIAN CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
13
Recensione:
Indirizzi per estratti:
Citazione:
J. Rotmensch et al., "IN-VITRO AND IN-VIVO STUDIES ON THE DEVELOPMENT OF THE ALPHA-EMITTINGRADIONUCLIDE BISMUTH-212 FOR INTRAPERITONEAL USE AGAINST MICROSCOPIC OVARIAN-CARCINOMA", American journal of obstetrics and gynecology, 176(4), 1997, pp. 833-840

Abstract

OBJECTIVE: Our objective was to develop the alpha-emitting radionuclide bismuth 212 for possible intraperitoneal use against microscopic ovarian cancer. STUDY DESIGN: The radiobiologic effectiveness of bismuth212 was compared in vitro to x rays and chromic phosphate phosphorus 32). The distribution, toxicity, and maximum tolerated dose of bismuth212 were determined after intraperitoneal administration in animal models. Dose estimates in animals and humans were made. RESULTS: In in vitro studies bismuth 212 was three times more effective in eradicatingtumor cells grown in monolayers and in 800 mu m spheroids. In in vivostudies bismuth 212 was distributed uniformly after intraperitoneal administration. The maximum tolerated dose in rabbits was 60 mCi. Therewas reversible hematologic toxicity with minimal organ damage. Bismuth 212 prolonged survival and cured up to 40% of animals inoculated with Ehrlich carcinoma cells. Dose estimates made from these studies indicated that dosages administered were effective in eradicating tumor cells and were within the radiotolerance of normal human tissue. CONCLUSION: Bismuth 212 appears to be a suitable candidate for intraperitoneal use against microscopic ovarian cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 19:54:53